Electronic Supporting Information

Visible-Light-Induced Mn(0)-Catalyzed Direct C–3 Mono-, Di- and Perfluoroalkylations of 2*H*-Indazoles

Sudip Laru, Suvam Bhattacharjee and Alakananda Hajra*

Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India

Email: alakananda.hajra@visva-bharati.ac.in

Contents

Sl. No.	Topics	Page No.
1	General information	S3
2	Light information	S3
3	Pictorial presentation of the reaction set-up	S4
4	Experimental procedures	S5-S6
5	Gram-scale preparation of 3ba	S7
6	Synthetic utility of C-3 difluoroacetated products: Synthesis	S7-S8
	of 3-(difluoromethyl)-2-(<i>p</i> -tolyl)-2 <i>H</i> -indazole (6bc)	
7	Structure determination (X-ray crystallographic data for 3fa)	S8-S10
8	Mechanistic studies of the reaction	S11
9	Physical data of the compounds	S12-S30
10	References	S31
11	NMR spectra [1 H, 13 C{ 1 H}, 19 F, and 31 P] of synthesized products	S32-S143

<u>1. General information:</u>

All reagents were purchased from commercial sources and used without further purification. ¹H NMR spectra were determined on 400 MHz spectrometer as solutions in CDCl₃. Chemical shifts are expressed in parts per million (δ) and the signals were reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and coupling constants (*J*) were given in Hz. ¹³C{¹H} NMR spectra were recorded at 100 MHz in CDCl₃ solution. Moreover, ¹⁹F {¹H decoupled} and ³¹P NMR spectra were recorded at 376.5 MHz, and 162 MHz in CDCl₃ solution. Chemical shifts are referenced to CDCl₃ (δ = 7.26 for ¹H and δ = 77.16 for ¹³C{¹H} NMR) as internal standard. High-resolution mass spectra (HRMS) were collected using electrospray ionization (ESI) on a time-of-flight (TOF) mass spectrometer. TLC was done on silica gel coated glass slide. All solvents were dried and distilled before use. All reactions involving moisture sensitive reactants were executed using oven dried glassware. All the 2*H*-indazoles¹ and bromodifluoroacetamide derivatives² were prepared by reported method. Melting points (mp.) were determined after recrystallization of solid compounds from a solution of dichloromethane/petroleum ether (1:3).

2. Light information:

Kessil 34 W blue LED (Model No. H150-BLUE) was used as a light source for light promoted reactions.

Rating of LED: 24VDC 1.5A 34W

Model: H150-BLUE

Range of wavelength: 450-530 nm. Manufacturer: Kessil, 1689 Regatta blvd, Richmond, CA94804 (www.kessil.com).

3. Pictorial presentation of the reaction set-up:

The Borosilicate glass reaction tube was used to carry out light-promoted reaction. The reaction tube was kept 5-7 cm apart from the exposed of Kessil 34 W blue LED. Regular fan was used to keep up the temperature 28 to 30 °C during the reaction. We did not use any filter.



Fig: S1.1: LED reaction set-up



Fig: S1.2: LED reaction set-up

4. Experimental procedures:

4.1. Typical experimental procedure for the synthesized compounds 3aa-3pa:



A mixture of 2-Arylindazoles (0.2 mmol) (1), $BrCF_2PO(OEt)_2$ (0.4 mmol, 106.8 mg) (2a), $Mn_2(CO)_{10}$ (5 mol %, 3.9 mg), NaHCO₃ (2.0 equiv, 33.6 mg), and 1,4-Dioxane (2 mL) was added to an oven-dried reaction vessel (tube) equipped with a magnetic stirrer, and the reaction vessel was irradiated with Kessil 34 W blue LED at room temperature under nitrogen atmosphere for 36 h. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure products **3aa-3pa**.



4.2. Experimental procedure for the synthesized compounds 3ab-3ge:

A mixture of 2-Arylindazoles (0.2 mmol) (1), XCF_2R^4 (X=Br, I, R^4 = -COOEt, amides, $-C_3F_7$) (0.4 mmol) (2), $Mn_2(CO)_{10}$ (5 mol %, 3.9 mg), NaHCO₃ (2.0 equiv, 33.6 mg), and 1,4-Dioxane (2 mL) was added to an oven-dried reaction tube equipped with a magnetic stirrer, and the reaction vessel was irradiated with Kessil 34 W blue LED at room temperature under nitrogen atmosphere for 36 h. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure products **3ab-3ge**.

4.3. Experimental procedure for the synthesized compounds 5af-5nf:



A mixture of 2-Arylindazoles (0.2 mmol) (1), BrCFHCO(OEt)₂ (0.4 mmol, 74 mg) (4f), $Mn_2(CO)_{10}$ (5 mol %, 3.9 mg), NaHCO₃ (2.0 equiv, 33.6 mg), and 1,4-Dioxane (2 mL) was added to an oven-dried reaction vessel (tube) equipped with a magnetic stirrer, and the reaction vessel was irradiated with Kessil 34 W blue LED at room temperature under nitrogen atmosphere for 36 h. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure products **5af-5nf**.

5. Gram-scale preparation of 3ba:



A mixture of 2-(*p*-tolyl)-2*H*-indazole (4.0 mmol, 832.0 mg) (**1b**), $BrCF_2PO(OEt)_2$ (8.0 mmol, 2.14 g) (**2a**), $Mn_2(CO)_{10}$ (5 mol %, 78 mg), $NaHCO_3$ (2.0 equiv, 672 mg), and 1,4-Dioxane (30 mL) was added to an oven-dried reaction vessel (tube) equipped with a magnetic stirrer, and the reaction vessel was irradiated with Kessil 34 W blue LED at room temperature under nitrogen atmosphere for 36 h. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na_2SO_4 . The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure product **3ba** (1.16 g, 74%) as a yellow solid.

<u>6. Synthetic utility of C–3 difluoroacetated products: Synthesis of 3-(difluoromethyl)-2-</u> (*p*-tolyl)-2*H*-indazole (6bc):



A mixture of ethyl 2,2-difluoro-2-(2-(p-tolyl)-2H-indazol-3-yl)acetate (0.3 mmol, 99 mg) (**3bb**), K₂CO₃ (2.0 equiv, 82.9 mg) and 2 mL of MeOH: H₂O (1:1) as solvent in an ovendried reaction tube equipped with magnetic bar was stirred for 2 h at room temperature. Thereafter, evaporation of the solvent mixture was done and then workup with crude ethyl

acetate and water. Finally, the crude mixture was taken in an oven-dried reaction tube and added 1.0 equiv of CsF in 2 mL of DMF and stirred at 150 ⁰C temperature for 12 h. After the completion of the reaction (monitored by TLC), the crude reaction mixture was extracted with ethyl acetate. The organic extract was dried over anhydrous Na₂SO₄ and concentrated. The product was subjected to column chromatography (silica gel, 60-120 mesh), eluting with petroleum ether and ethyl acetate (9:1) to afford the product **6bc** (85%, 65 mg) as white solid.

7. Structure determination (X-ray crystallographic data for 3fa):

The colourless crystal of **3fa** was obtained by crystallization from a solution in dichloromethane/petroleum ether after purification by column chromatography. Chemical formula: $C_{19}H_{18}F_5N_2O_3P$.

For single crystal structure determination, a suitable single crystal was carefully selected under a polarizing microscope and glued carefully to a thin glass fiber. The single crystal data were collected on a Bruker D8 Quest diffractometer at 293 (2) K (Fig. S2). The X-ray generator was operated at 50 kV and 1 mA using Mo K α radiation ($\lambda = 0.71073$ Å), controlled by the APEX3 software package³. Data were collected with ω scan width of 0.3°. A total of 408 frames were collected in three different setting of φ (0, 90, 180°) keeping sample-to-detector distance fixed at 6.03 cm and the detector position (2 θ) fixed at -25°. The data were reduced using SAINTPLUS, and an empirical absorption correction was applied using the SADABS program. The structure was solved and refined using SHELXL97⁴ present in the OLEX 2⁵ suit of programs.



Fig: S2.1

Wavelength	0.71073 Å		
Formula	C ₁₉ H ₁₈ F ₅ N ₂ O ₃ P	$C_{19}H_{18}F_5N_2O_3P$	
Crystal system	Monoclinic	Monoclinic	
Space group	P 2 ₁ /n	P 2 ₁ /n	
Unit cell dimensions	a = 8.144(2) Å	$\alpha = 90^{\circ}$	
	b = 9.764(2) Å	$\beta = 98.77(3)^{\circ}$	
	c = 26.580(5) Å	$\gamma = 90^{\circ}$	
Volume	2088.9(8) Å ³		
Z	4][
R-factor (%)	7.7		

The crystallographic data have been deposited with the Cambridge Crystallographic Data Centre as a supplementary publication with a CCDC reference number CCDC 2191201. Datablock vb_0m_a - ellipsoid plot



Fig: S2.2

View of ORTEP diagram for the crystal structure of the compound **Diethyl (difluoro(2-(4-(trifluoromethyl)phenyl)-2H-indazol-3-yl)methyl)phosphonate (3fa)** (Thermal ellipsoid contour at 50% probability level).

8. Mechanistic studies of the reaction:



Fig: S3

Different radical inhibitors such as 2,6-di-*tert*-butyl-4-methyl phenol (BHT), benzoquinone (BQ), and 2,2,6,6-tetramethyl-1-oxylpiperidine (TEMPO) in the reaction which completely suppressed the desired product of the reaction (Fig S3, eq A). Furthermore, the radical adduct diethyl (1,1-difluoro-3,3-diphenylallyl)phosphonate (**7a**) was produced in 80% yield by the addition of 2.0 equiv of 1,1-diphenylethylene to the present reactions (Fig S3, eq B). The above experimental outputs suggest that a radical pathway might be involved in the reaction.

9. Physical data of the compounds:

Diethyl (difluoro(2-phenyl-2H-indazol-3-yl)methyl)phosphonate (3aa):



Yellow liquid (60 mg, 80%); $R_f 0.4$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.85 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.68–7.66 (m, 2H), 7.52–7.48 (m, 3H), 7.39–7.35 (m, 1H), 7.25–7.21 (m, 1H), 4.19–4.01 (m, 4H), 1.25 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.5, 140.7, 129.6, 128.5, 127.2 (d, $J_{C-F} = 5.0$ Hz) 125.9, 124.1, 122.3, 120.7, 118.2, 117.0, 114.8, 65.2 (d, $J_{C-F} = 7.0$ Hz), 16.4 (d, $J_{C-F} = 6.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -101.6 (d, $J_{F-P} = 116.71$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.94 (t, $J_{P-F} = 118.2$ Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₂₀F₂N₂O₃P]⁺: 381.1174; Found 381.1159.

Diethyl (difluoro(2-(p-tolyl)-2H-indazol-3-yl)methyl)phosphonate (3ba):



Yellow solid (64 mg, 82%); mp. 64–65 °C; $R_f 0.4$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.85 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.38–7.34 (m, 1H), 7.29–7.25 (m, 2H), 7.23–7.20 (m, 1H), 4.20–3.99 (m, 4H), 2.44 (s, 3H), 1.25 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.5, 139.6, 138.3, 129.0,

127.0 (d, $J_{C-F} = 8.0$ Hz), 123.9 (d, $J_{C-F} = 9.0$ Hz), 122.3, 120.7, 119.7, 118.1, 117.4, 114.5, 65.1 (d, $J_{C-F} = 7.0$ Hz), 21.4, 16.4 (d, $J_{C-F} = 5.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -101.5 (d, $J_{F-P} = 116.7$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.97 (t, $J_{P-F} = 116.6$ Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₉H₂₂F₂N₂O₃P]⁺: 395.1331; Found 395.1314

Diethyl (difluoro(2-(4-methoxyphenyl)-2H-indazol-3-yl)methyl)phosphonate (3ca):



Yellow solid (66 mg, 81%); mp. 84–85 °C; $R_f 0.4$ (PET:EtOAc = 3:2); ¹H NMR (CDCl₃, 400 MHz): δ 7.84 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.36 (t, J = 8.0 Hz, 1H), 7.23–7.20 (m, 1H), 7.00–6.96 (m, 2H), 4.19–4.02 (m, 4H), 3.87 (s, 3H), 1.25 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 160.3, 148.4, 133.6, 128.4, 127.0, 126.0 (d, J_{C-F} = 45.0 Hz), 123.9, 122.3, 120.7, 118.1, 114.8, 113.5, 65.1 (d, J_{C-F} = 6.0 Hz), 55.6, 16.4 (d, J_{C-F} = 5.0 Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -101.8 (d, J_{F-P} = 112.9 Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.97 (t, J_{P-F} = 116.6 Hz); Anal. Calcd for HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₉H₂₂F₂N₂O₄P]⁺: 411.1280; Found 411.1285.

Diethyl ((2-(4-chlorophenyl)-2H-indazol-3-yl)difluoromethyl)phosphonate (3da):



Yellow solid (70 mg, 85%); mp. 80–81 °C; $R_f 0.5$ (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.83 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.38 (t, J = 8.4 Hz, 1H), 7.26–7.21 (m, 1H), 4.23–4.03 (m, 4H), 1.27 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.7, 139.2, 135.6 128.6 (d, J_{C-F} = 22.0 Hz), 127.4, 124.3, 122.4, 120.6, 119.4 (d, J_{C-F} = 44.0 Hz), 118.2, 117.1 (d, J_{C-F} = 38.0 Hz), 114.7, 65.3 (d, J_{C-F} = 6.0 Hz), 16.4 (d, J_{C-F} = 6.0 Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ - 101.9 (d, J_{F-P} = 116.7 Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.82 (t, J_{P-F} = 115.0 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₉ClF₂N₂O₃P]⁺: 415.0784; Found 415.0790.

Diethyl ((2-(3-bromophenyl)-2H-indazol-3-yl)difluoromethyl)phosphonate (3ea):



Yellow liquid (76 mg, 83%); $R_f 0.5$ (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.89 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.69–7.63 (m, 2H), 7.40–7.35 (m, 2H), 7.25–7.21 (m, 1H), 4.25–4.05 (m, 4H), 1.28 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.7, 141.7, 132.7, 130.4, 129.7, 127.4, 126.0, 124.3, 122.4 (d, $J_{C-F} = 3.0$ Hz), 121.8, 120.7, 118.2, 117.1 (d, $J_{C-F} = 37.0$ Hz), 114.5 (d, $J_{C-F} = 35.0$ Hz), 65.3 (d, $J_{C-F} = 7.0$ Hz), 16.4 (d, $J_{C-F} = 5.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -101.7 (d, $J_{F-P} = 112.9$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.91 (t, $J_{P-F} = 113.4$ Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₉BrF₂N₂O₃P]⁺: 459.0279; Found 459.0266.

Diethyl (difluoro(2-(4-(trifluoromethyl)phenyl)-2H-indazol-3-yl)methyl)phosphonate (3fa):



White solid (71 mg, 80%); mp. 79–80 °C; $R_f 0.5$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.89–7.83 (m, 3H), 7.77 (d, J = 8.8 Hz, 3H), 7.39 (t, J = 8.4 Hz, 1H), 7.27–7.23 (m, 1H), 4.24–4.04 (m, 4H), 1.27 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.9, 143.5, 131.3 (q, $J_{C-F} = 63.0$ Hz), 127.6 (d, $J_{C-F} = 15.0$ Hz), 125.7 (q, $J_{C-F} = 4.0$ Hz), 125.1, 124.5, 122.5 (t, $J_{C-F} = 7.0$ Hz), 120.7, 118.2, 116.9, 114.7 (d, $J_{C-F} = 3.0$ Hz), 65.3 (d, $J_{C-F} = 7.0$ Hz), 16.4 (d, $J_{C-F} = 5.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -62.6, -101.6 (d, $J_{F-P} = 116.7$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.79 (t, $J_{P-F} = 113.4$ Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₉H₁₉F₅N₂O₃P]⁺: 449.1048; Found 449.1053.

Diethyl ((5-chloro-2-(p-tolyl)-2H-indazol-3-yl)difluoromethyl)phosphonate (3ga):



Reddish yellow liquid (72 mg, 84%); $R_f 0.4$ (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.82 (s, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.31–7.25 (m, 3H), 4.21–4.05 (m, 4H), 2.43 (s, 3H), 1.28 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 146.7, 142.0, 139.9, 137.9, 129.7, 129.1, 128.5, 126.7, 122.6, 119.6 (d, $J_{C-F} = 18.0$ Hz), 116.8, 114.3 (d, $J_{C-F} = 37.0$ Hz), 65.2 (d, J = 7.0 Hz), 21.4, 16.4 (d, J = 6.0 Hz); ¹⁹F NMR

(376.5 MHz, CDCl₃): δ -102.1 (d, $J_{F-P} = 112.9$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 4.65 (t, $J_{P-F} = 116.6$ Hz); HRMS (ESI–TOF) m/z: [M + H]+ Calcd for [C₁₉H₂₁ClF₂N₂O₃P]⁺: 429.0941; Found 429.0925.

Diethyl (difluoro(5-fluoro-2-phenyl-2H-indazol-3-yl)methyl)phosphonate (3ha):



Yellow solid (65 mg, 82%); mp. 81–82 °C; $R_f 0.4$ (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.77–7.74 (m, 1H), 7.67–7.65 (m, 2H), 7.53–7.48 (m, 3H), 7.43 (d, J = 9.6 Hz, 1H), 7.20–7.15 (m, 1H), 4.22–4.03 (m, 4H), 1.27 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 159.5 (d, J_{C-F} = 241.0 Hz), 145.9, 140.6, 129.7, 128.5, 127.1, 122.0 (d, J_{C-F} = 11.0 Hz), 120.4 (d, J_{C-F} = 10.0 Hz), 119.0 (d, J_{C-F} = 29.0 Hz), 116.8, 114.6, 103.5 (d, J_{C-F} = 26.0 Hz), 65.2 (d, J_{C-F} = 7.0 Hz), 16.4 (d, J_{C-F} = 5.0 Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -101.9 (d, J_{F-P} = 112.9 Hz), -116.2; ³¹P NMR (CDCl₃, 162 MHz): δ 4.81 (t, J_{P-F} = 116.6 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₉F₃N₂O₃P]⁺: 399.1080; Found 399.1085.

Diethyl ((2-(3-chlorophenyl)-5-fluoro-2H-indazol-3-yl)difluoromethyl)phosphonate (3ia):



Yellow solid (67 mg, 78%); mp. 78–79 °C; R_f 0.4 (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.77–7.72 (m, 2H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.51–7.49 (m, 1H), 7.46–7.42 (m, 2H),

7.22–7.16 (m, 1H), 4.27–4.08 (m, 4H), 1.30 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 161.9, 159.6 (d, $J_{C-F} = 244.0$ Hz), 146.1, 141.4, 134.2, 129.7 (d, $J_{C-F} = 36.0$ Hz), 127.5, 125.4, 123.3, 122.0 (t, $J_{C-F} = 5.0$ Hz), 120.5 (d, $J_{C-F} = 9.0$ Hz), 119.4 (d, $J_{C-F} = 29.0$ Hz), 114.5, 103.5 (d, $J_{C-F} = 26.0$ Hz) 65.3 (d, $J_{C-F} = 7.0$ Hz), 16.4 (d, $J_{C-F} = 5.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -102.1 (d, $J_{F-P} = 112.9$ Hz), -115.6; ³¹P NMR (CDCl₃, 162 MHz): δ 4.78 (t, $J_{P-F} = 115.0$ Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₈ClF₃N₂O₃P]⁺: 433.0690; Found 433.0696.

Diethyl (difluoro(3-methyl-1H-indol-2-yl)methyl)phosphonate (30a):⁶



Brown gummy (47 mg, 75%); $R_f 0.45$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 8.91 (s, br, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.28–7.25 (m, 1H), 7.17–7.13 (m, 1H), 4.28–4.13 (m, 4H), 2.47 (q, J = 2.8 Hz, 2.4 Hz, 3H), 1.32 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 136.0, 128.4, 124.1, 123.2 (d, $J_{C-F} = 13.0$ Hz), 119.8 (d, $J_{C-F} = 15.0$ Hz), 117.6, 115.4, 114.1 (t, $J_{C-F} = 3.0$ Hz), 111.7, 65.3 (d, $J_{C-F} = 6.0$ Hz), 16.4 (d, $J_{C-F} = 5.0$ Hz), 8.8; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -105.1 (d, $J_{F-P} = 112.9$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 5.75 (t, $J_{P-F} = 115.0$ Hz).

Diethyl (difluoro(1-methyl-1H-indol-2-yl)methyl)phosphonate (3pa):⁶



Brown gummy (38 mg, 61%); R_f 0.50 (PET:EtOAc = 3:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.65 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.34–7.30 (m, 1H), 7.17–7.13 (m, 1H), 6.93 (d, J = 0.8 Hz, 1H), 4.30–4.16 (m, 4H), 3.92 (s, 3H), 1.34 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 139.1, 127.7, 126.3, 123.9, 121.9, 120.3, 117.2, 109.9, 105.4 (t, $J_{C-F} = 10.0$ Hz), 65.2 (d, $J_{C-F} = 7.0$ Hz), 31.7, 16.4 (d, $J_{C-F} = 6.0$ Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -102.5 (d, $J_{F-P} = 112.9$ Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 5.10 (t, $J_{P-F} = 115.0$ Hz).

Ethyl 2,2-difluoro-2-(2-phenyl-2H-indazol-3-yl)acetate (3ab):



Light yellow solid (53 mg, 84%); mp. 140–141 °C; $R_f 0.6$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.56–7.51 (m, 4H), 7.42–7.38 (m, 1H), 7.28–7.24 (m, 1H), 4.04 (q, J = 8.8 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 162.1 (t, J_{C-F} = 35.0 Hz), 148.5, 139.6, 130.0, 129.0, 127.2, 126.7, 126.1 (d, J_{C-F} = 33.0 Hz), 124.5, 122.1, 120.2 (t, J_{C-F} = 3.0 Hz), 118.3, 110.9 (d, J_{C-F} = 249.0 Hz), 63.7, 13.7; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -94.5; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₁₅F₂N₂O₂]⁺: 317.1096; Found 317.1104.

Ethyl 2,2-difluoro-2-(2-(p-tolyl)-2H-indazol-3-yl)acetate (3bb):



Yellow solid (53 mg, 81%); mp. 132–133 °C; $R_f 0.65$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.87 (d, J = 8.8 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.42–7.37 (m, 3H), 7.30 (d, J= 8.0 Hz, 2H), 7.27–7.23 (m, 1H), 4.05 (q, J = 7.2 Hz, 2H), 2.45 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 162.2 (t, J_{C-F} = 50.0 Hz), 148.5, 140.2, 137.1, 130.2 (d, J_{C-F} = 4.0 Hz), 129.6, 127.1, 126.5, 124.3, 122.1, 120.2 (t, J_{C-F} = 5.0 Hz), 118.2, 111.0 (t, J_{C-F} = 248.0 Hz), 63.7, 21.4, 13.7; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -94.74; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₇F₂N₂O₂]⁺: 331.1253; Found 331.1258.

Ethyl 2-(2-(4-chlorophenyl)-2H-indazol-3-yl)-2,2-difluoroacetate (3db):



Yellow liquid (55 mg, 79%); R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.85 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.506–7.500 (m, 4H), 7.42–7.38 (m, 1H), 7.28–7.23 (m, 1H), 4.13 (q, J = 7.2 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 162.2 (t, $J_{C-F} = 34.0$ Hz), 148.7, 138.2, 136.1, 129.9, 129.2, 128.0, 127.5, 124.7, 122.3 (d, $J_{C-F} = 13.0$ Hz), 120.1 (t, $J_{C-F} = 4.0$ Hz), 118.3, 110.8 (t, $J_{C-F} = 250.0$ Hz), 63.9, 13.8; ¹⁹**F NMR** (376.5 MHz, CDCl3): δ -95.0; **HRMS** (ESI–TOF) m/z: $[M + H]^+$ Calcd for $[C_{17}H_{14}ClF_2N_2O_2]^+$: 351.0706; Found 351.0711.

Ethyl 2-(5-chloro-2-(p-tolyl)-2H-indazol-3-yl)-2,2-difluoroacetate (3gb):



Yellow liquid (54 mg, 75%); $R_f 0.6$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.87 (s, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.34–7.29 (m, 3H), 4.05 (q, J = 7.2 Hz, 2H), 2.45 (s, 3H), 1.14 (t, J = 7.6 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 161.9 (t, $J_{C-F} = 34.0$ Hz), 146.8, 140.5, 136.7, 130.3 (d, $J_{C-F} = 12.0$ Hz), 129.7, 128.7, 126.3, 122.4, 120.9 (d, $J_{C-F} = 39.0$ Hz), 119.8, 119.0 (t, $J_{C-F} = 3.0$ Hz), 110.7 (t, $J_{C-F} = 249.0$ Hz), 63.8, 21.4, 13.7; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -94.9. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₆ClF₂N₂O₂]⁺: 365.0863; Found 365.0887.

Ethyl 2-(5-chloro-2-phenyl-2H-indazol-3-yl)-2,2-difluoroacetate (3jb):



White solid (58 mg, 83%); mp. 165–166 °C; R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.88 (s, 1H), 7.76–7.73 (m, 1H), 7.55–7.51 (m, 5H), 7.35–7.32 (m, 1H), 4.04 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 161.9 (t, $J_{C-F} = 35.0$ Hz), 146.9, 139.3, 130.3 (d, $J_{C-F} = 8.0$ Hz), 129.7, 129.2, 128.8, 126.6, 122.5 (d,

 $J_{C-F} = 7.0 \text{ Hz}$, 120.9, 119.8, 119.1 (t, $J_{C-F} = 3.0 \text{ Hz}$), 110.7 (t, $J_{C-F} = 248.0 \text{ Hz}$), 63.9, 13.7; ¹⁹**F NMR** (376.5 MHz, CDCl₃): δ -94.8; **HRMS** (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₁₄ClF₂N₂O₂]⁺: 351.0706; Found 351.0712.

2,2-Difluoro-1-morpholino-2-(2-(p-tolyl)-2H-indazol-3-yl)ethan-1-one (3bc):



Light yellow liquid (63 mg, 85%); $R_f 0.4$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.79 (t, J = 10.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.41–7.37 (m, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.27–7.23 (m, 1H), 3.60–3.58 (m, 2H), 3.44–3.42 (m, 2H), 3.37–3.35 (m, 2H), 3.20–3.18 (m, 2H), 2.44 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 160.0 (t, $J_{C-F} = 31.0$ Hz), 148.5, 140.2, 137.2, 129.6, 127.2, 126.7 (d, $J_{C-F} = 32.0$ Hz), 126.2, 124.6, 121.4, 119.7, 118.5, 112.3 (t, $J_{C-F} = 247.0$ Hz), 66.4, 66.1, 46.3, 43.3, 21.4; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -88.4; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₀H₂₀F₂N₃O₂]⁺: 372.1518; Found 372.1524.

2,2-difluoro-N-(p-tolyl)-2-(2-(p-tolyl)-2H-indazol-3-yl)acetamide (3bd):



Colourless liquid (65 mg, 84%); $R_f 0.5$ (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.89 (d, J = 8.8 Hz, 1H), 7.81–7.73 (m, 2H), 7.41–7.32 (m, 3H), 7.26–7.23 (m, 1H), 7.18 (d, J = 8.8 Hz, 3H), 7.13–7.08 (m, 2H), 2.31, 2.30 (2s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 159.7 (t, $J_{C-F} = 30.0$ Hz), 148.4, 140.4, 136.9, 135.6, 133.0, 130.2 (d, $J_{C-F} = 11.0$ Hz), 129.6 (t, $J_{C-F} = 14.0$ Hz), 127.0 (d, $J_{C-F} = 17.0$ Hz), 126.4 (d, $J_{C-F} = 33.0$ Hz), 125.5, 124.5, 122.4, 121.1 (d, $J_{C-F} = 16.0$ Hz), 120.2 (d, $J_{C-F} = 19.0$ Hz), 118.2, 112.5 (t, $J_{C-F} = 252.0$ Hz), 21.3, 21.0; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -94.7; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₃H₂₀F₂N₃O]⁺: 392.1569; Found 392.1597.

3-(Perfluorobutyl)-2-(p-tolyl)-2H-indazole (3be):



White solid (64 mg, 76%); mp. 62–63 °C; $R_f 0.85$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.83–7.76 (m, 2H), 7.43–7.40 (m, 1H), 7.36–7.34 (m, 2H), 7.32–7.28 (m, 3H), 2.46 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.3, 140.3, 137.6, 130.3, 129.3, 127.3, 126.8 (t, $J_{C-F} = 8.0$ Hz), 125.4, 125.2, 123.2 (d, $J_{C-F} = 13.0$ Hz), 122.4, 122.1 (d, $J_{C-F} = 8.0$ Hz), 121.1 (d, $J_{C-F} = 7.0$ Hz), 119.8, 118.5, 21.4; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -80.8–80.9 (m, 3F), -103.7–103.8 (m, 2F), -121.4–-121.5 (m, 2F), -125.9–-126.0 (m, 2F); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₂F₉N₂]⁺: 427.0851; Found 427.0857.

2-(4-Chlorophenyl)-3-(perfluorobutyl)-2H-indazole (3de):



White solid (65 mg, 73%); mp. 59–60 °C; $R_f 0.85$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.81 (d, J = 9.2 Hz, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.54–7.48 (m, 2H), 7.45–7.42 (m, 3H), 7.33–7.30 (m, 1H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.6, 138.6 (d, J_{C-F} = 12.0 Hz), 136.4, 130.0, 129.9, 129.0, 128.5, 127.7, 125.7 (d, J_{C-F} = 27.0 Hz), 123.3, 122.6, 122.4 (q, J_{C-F} = 8.0 Hz), 122.0 (t, J_{C-F} = 8.0 Hz), 119.7, 118.5; ¹⁹F NMR (376.5 MHz, CDCl₃): δ - 80.8–80.9 (m, 3F), -103.6–103.7 (m, 2F), -121.4–-121.5 (m, 2F), -125.9–-126.0 (m, 2F); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₉ClF₉N₂]⁺: 447.0305; Found 447.0311.

5-Chloro-3-(perfluorobutyl)-2-(p-tolyl)-2H-indazole (3ge):



White liquid (66 mg, 72%); $R_f 0.85$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.78–7.75 (m, 2H), 7.37–7.33 (m, 3H), 7.31–7.29 (m, 2H), 2.46 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 146.7, 140.6, 138.1, 137.4, 136.8, 131.3, 130.3 (d, $J_{C-F} = 6.0$ Hz), 129.4, 128.9, 126.6 (q, $J_{C-F} = 15.0$ Hz), 123.5 (d, $J_{C-F} = 12.0$ Hz), 123.2 (d, $J_{C-F} = 6.0$ Hz), 121.2 (t, $J_{C-F} = 17.0$ Hz), 120.1, 118.4 (d, $J_{C-F} = 12.0$ Hz), 21.4; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -80.8–80.9 (m, 3F), -103.8–103.9 (m, 2F), -121.3–121.4 (m, 2F), -125.8–125.9 (m, 2F); **HRMS** (ESI–TOF) m/z: $[M + H]^+$ Calcd for $[C_{18}H_{11}ClF_9N_2]^+$: 461.0462; Found 461.0467.

Ethyl 2-fluoro-2-(2-phenyl-2H-indazol-3-yl)acetate (5af):



Yellow liquid (45 mg, 77%); R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.82 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.70–7.67 (m, 2H), 7.61–7.53 (m, 3H), 7.40–7.37 (m, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.12 (d, J = 47.6 Hz, 1H), 4.30–4.15 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.7 (d, $J_{C-F} = 30.0$ Hz), 148.8, 139.0, 129.8, 129.6, 127.3 (d, $J_{C-F} = 25.0$ Hz), 126.4, 124.0, 121.8, 121.2 (d, $J_{C-F} = 6.0$ Hz), 119.3, 118.3, 80.4 (d, $J_{C-F} = 184.0$ Hz), 62.7, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -168.7 (d, J = 48.9 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₁₆FN₂O₂]⁺: 299.1190; Found 299.1196.

Ethyl 2-fluoro-2-(2-(p-tolyl)-2H-indazol-3-yl)acetate (5bf):



Light yellow solid (51 mg, 82%); mp. 109–110 °C; $R_f 0.65$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.81 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.39–7.36 (m, 3H), 7.23–7.19 (m, 1H), 6.11 (d, J = 47.6 Hz, 1H), 4.30–4.15 (m, 2H),

2.47 (s, 3H), 1.19 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.7 (d, $J_{C-F} = 30.0$ Hz), 148.7, 140.1, 136.4, 130.1, 127.4, 127.1 (d, $J_{C-F} = 7.0$ Hz), 126.1, 123.8, 121.3 (d, $J_{C-F} = 60.0$ Hz), 119.3, 118.3, 80.4 (d, $J_{C-F} = 184.0$ Hz), 62.6, 21.4, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -168.7 (d, J = 48.9 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₈FN₂O₂]⁺: 313.1347; Found 313.1352.

Ethyl 2-fluoro-2-(2-(4-methoxyphenyl)-2H-indazol-3-yl)acetate (5cf):



Yellow liquid (49 mg, 75%); $R_f 0.5$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.80 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.61–7.57 (m, 2H), 7.38 (t, J = 8.0 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.08–7.04 (m, 2H), 6.09 (d, J = 47.6 Hz, 1H), 4.29–4.17 (m, 2H), 3.89 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.7 (d, $J_{C-F} = 30.0$ Hz), 160.6, 148.6, 134.3, 131.8, 127.6 (d, $J_{C-F} = 16.0$ Hz), 127.1 (d, $J_{C-F} = 21.0$ Hz), 126.2, 123.8, 121.6, 119.2 (d, $J_{C-F} = 100.0$ Hz), 114.6, 80.4 (d, $J_{C-F} = 184.0$ Hz), 62.6, 55.8, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -168.7 (d, J = 52.7 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₈FN₂O₃]⁺: 329.1296; Found 329.1301.

Ethyl 2-(2-(4-bromophenyl)-2H-indazol-3-yl)-2-fluoroacetate (5kf):



Yellow solid (58 mg, 78%); mp. 110–111 °C; $R_f 0.7$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.80 (d, J = 8.8 Hz, 1H), 7.73–7.70 (m, 3H), 7.60–7.56 (m, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.25–7.21 (m, 1H), 6.10 (d, J = 47.6 Hz, 1H), 4.29–4.18 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.4 (d, J_{C-F} = 29.0 Hz), 148.9 (d, J_{C-F} = 5.0 Hz), 141.4, 137.9, 132.8, 127.8, 127.4 (d, J_{C-F} = 5.0 Hz), 127.2, 124.1 (d, J_{C-F} = 21.0 Hz), 122.0, 119.3, 118.3, 80.2 (d, J_{C-F} = 185.0 Hz), 62.8, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ - 168.2 (d, J = 48.9 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₁₅BrFN₂O₂]⁺: 377.0295; Found 377.0295.

Ethyl 4-(3-(2-ethoxy-1-fluoro-2-oxoethyl)-2H-indazol-2-yl)benzoate (5lf):



Yellow liquid (51 mg, 70%); R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 8.27 (d, J = 8.4 Hz, 2H), 7.81 (t, J = 8.4 Hz, 3H), 7.74 (d, J = 8.8 Hz, 1H), 7.40 (t, J = 8.4 Hz, 1H), 7.26–7.22 (m, 1H), 6.13 (d, J = 47.6 Hz, 1H), 4.43 (q, J = 7.2 Hz, 2H), 4.28–4.17 (m, 2H), 1.43 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.4 (d, $J_{C-F} = 29.0$ Hz), 165.5, 149.0 (d, $J_{C-F} = 4.0$ Hz), 142.3, 131.6, 130.9, 127.6, 127.3 (d, $J_{C-F} = 24.0$ Hz), 126.1, 124.3, 122.1, 119.3, 118.4, 80.1 (d, $J_{C-F} = 185.0$ Hz), 62.8, 61.7, 14.4, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -168.2 (d, J = 45.1 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₀H₂₀FN₂O₄]⁺: 371.1402; Found 371.1407.



Yellow liquid (46 mg, 74%); R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.81 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.51 (s, 1H), 7.48–7.43 (m, 2H), 7.40–7.35 (m, 2H), 7.21 (t, J = 7.6 Hz, 1H), 6.13 (d, J = 47.2 Hz, 1H), 4.31–4.16 (m, 2H), 2.47 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.7 (d, $J_{C-F} = 29.0$ Hz), 148.7 (d, $J_{C-F} = 3.0$ Hz), 139.9, 138.8, 130.6, 129.3, 127.3, 127.1 (d, $J_{C-F} = 4.0$ Hz), 126.9, 123.9, 123.3, 121.7, 119.3, 118.3, 80.4 (d, $J_{C-F} = 184.0$ Hz), 62.6, 21.4, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -168.7 (d, J = 45.1 Hz).

Ethyl 2-(2-(tert-butyl)-2H-indazol-3-yl)-2-fluoroacetate (5nf):



Colourless liquid (26 mg, 47%); $R_f 0.65$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.73 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.29-7.26 (m, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.64 (d, J = 47.2 Hz, 1H), 4.35-4.22 (m, 2H), 1.88 (s, 9H), 1.21 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 167.0 (d, $J_{C-F} = 30.0$ Hz), 146.2 (d, $J_{C-F} = 5.0$ Hz), 125.9 (d, $J_{C-F} = 8.0$ Hz), 125.6, 123.0 (d, $J_{C-F} = 35.0$ Hz), 120.3, 119.5 (d, $J_{C-F} = 27.0$ Hz), 118.1, 81.0 (d, $J_{C-F} = 184.0$ Hz), 63.0, 62.5, 31.5, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -169.5 (d, J = 48.9 Hz); Anal. Calcd for C₁₅H₁₉FN₂O₂: C, 64.73; H, 6.88; N, 10.07%; Found C, 64.54; H, 6.93; N, 10.18%.

Ethyl 2-(5-chloro-2-phenyl-2H-indazol-3-yl)-2-fluoroacetate (5jf):



Yellow solid (55 mg, 83%); mp. 83–84 °C; $R_f 0.6$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.76–7.74 (m, 2H), 7.68–7.65 (m, 2H), 7.61–7.56 (m, 3H), 7.33–7.30 (m, 1H), 6.08 (d, J = 47.2 Hz, 1H), 4.32–4.18 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.3 (d, $J_{C-F} = 29.0$ Hz), 147.1 (d, $J_{C-F} = 3.0$ Hz), 138.7, 130.1, 129.8 (d, $J_{C-F} = 3.0$ Hz), 129.7, 128.7, 127.1 (d, $J_{C-F} = 26.0$ Hz), 126.3, 122.1, 119.9, 118.2, 80.3 (d, $J_{C-F} = 186.0$ Hz), 62.8, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -169.4 (d, J = 41.4 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₇H₁₅ClFN₂O₂]⁺: 333.0801; Found 333.0806.

Ethyl 2-(5-chloro-2-(p-tolyl)-2H-indazol-3-yl)-2-fluoroacetate (5gf):



Yellow solid (55 mg, 80%); mp. 109–110 °C; R_f 0.65 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.74 (d, J = 9.2 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.32–7.29 (m, 1H), 6.06 (d, J = 47.2 Hz, 1H), 4.31–4.19 (m, 2H), 2.47 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.4 (d, J_{C-F} = 29.0 Hz), 147.0, 140.4,

136.1, 130.2, 129.6, 128.6, 127.1 (d, $J_{C-F} = 25.0 \text{ Hz}$), 126.0, 122.0, 119.8, 118.2, 80.3 (d, $J_{C-F} = 185.0 \text{ Hz}$), 62.8, 21.4, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -169.4 (d, J = 48.9 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₈H₁₇ClFN₂O₂]⁺: 347.0957; Found 347.0957.

Ethyl 2-(2-(3-chlorophenyl)-5-fluoro-2H-indazol-3-yl)-2-fluoroacetate (5if):



Yellow solid (51 mg, 73%); mp. 81–82 °C; $R_f 0.7$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.80–7.77 (m, 1H), 7.73–7.72 (m, 1H), 7.60–7.52 (m, 3H), 7.33–7.31 (m, 1H), 7.22–7.18 (m, 1H), 6.08 (d, J = 47.2 Hz, 1H), 4.32–4.21 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 166.2 (d, $J_{C-F} = 29.0$ Hz), 160.8, 158.4, 146.3 (d, $J_{C-F} = 3.0$ Hz), 139.7, 135.5, 130.6, 130.2, 127.7 (d, $J_{C-F} = 9.0$ Hz), 125.4 (d, $J_{C-F} = 228.0$ Hz), 120.7 (d, $J_{C-F} = 10.0$ Hz), 119.4 (d, $J_{C-F} = 19.0$ Hz), 114.4, 102.1 (d, $J_{C-F} = 25.0$ Hz), 80.1 (d, $J_{C-F} = 186.0$ Hz), 62.9, 14.1; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -115.5, -168.9 (d, J = 45.1 Hz); HRMS (ESI–TOF) m/z: [M + Na]⁺ Calcd for [C₁₇H₁₃ClF₂N₂NaO₂]⁺: 373.0526; Found 373.0526.

3-(Difluoromethyl)-2-(p-tolyl)-2H-indazole (6bc):



White solid (43 mg, 85%); mp. 89–90 °C; $R_f 0.75$ (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.92–7.90 (m, 1H), 7.82–7.79 (m, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.41–7.35 (m, 3H), 7.26–7.23 (m, 1H), 6.89 (t, J = 50.0 Hz, 1H), 2.47 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 148.6 (d, J_{C-F} = 2.0 Hz), 140.2, 136.6, 130.2, 127.8, 127.3 (d, J_{C-F} = 31.0 Hz), 125.6, 124.1, 121.1, 119.9, 118.2, 110.0 (t, J_{C-F} = 233.0 Hz), 21.3; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -109.1 (d, J = 52.7 Hz); HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₁₅H₁₃F₂N₂]⁺: 259.1041; Found 259.1047.

Diethyl (1,1-difluoro-3,3-diphenylallyl)phosphonate (7a):



Light yellow liquid (58 mg, 80%); $R_f 0.4$ (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.33 (m, 3H), 7.32–7.27 (m, 5H), 7.26–7.23 (m, 2H), 6.19–6.10 (m, 1H), 4.27–4.17 (m, 4H), 1.34 (t, J = 7.2 Hz, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 151.1 (q, J_{C-F} = 8.0 Hz), 141.5, 138.2, 129.6, 129.0, 128.4, 128.0 (d, J_{C-F} = 7.0 Hz), 127.6, 118.6, 117.1 (q, J_{C-F} = 20.0 Hz), 116.4, 64.7 (d, J_{C-F} = 7.0 Hz), 16.5 (d, J_{C-F} = 6.0 Hz); ¹⁹F NMR (376.5 MHz, CDCl₃): δ -102.0 (d, J_{F-P} = 15.0 Hz), -102.3 (d, J_{F-P} = 15.0 Hz); ³¹P NMR (CDCl₃, 162 MHz): δ 6.70 (t, J_{P-F} = 113.4 Hz); HRMS (ESI–TOF) m/z: [M + Na]⁺ Calcd for [C₁₉H₂₁F₂NaO₃P]⁺: 389.1089; Found 389.1094.

10. References:

1. (a) M. R. Kumar, A. Park, N. Park and S. Lee, *Org. Lett.*, 2011, **13**, 3542; (b) D. Maiti, K. Mahanty and S. D. Sarkar, *Org. Lett.*, 2021, **23**, 1742; (c) G. Bogonda, H. Y. Kim and K. Oh, *Org. Lett.*, 2018, **20**, 2711.

2. (a) H. Morimoto, R. Fujiwara, Y. Shimizu, K. Morisaki and T. Ohshima, *Org. Lett.*, 2014, **16**, 2018; (b) L. Wang, X.-J. Wei, W.-L. Jia, J.-J. Zhong, L.-Z. Wu and Q. Liu, *Org. Lett.*, 2014, **16**, 5842.

3. 2009 Ed. APEX II, Bruker Analytical X-ray Systems Inc. Madison, WI, 2009.

4. G. M. Sheldrick, "SHELXL97. University of Gottingen, Germany, 1997.

5. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, OLEX2: J. *Appl. Crystallogr.* 2009, **42**, 339.

6. M. Singsardar, S. Mondal, S. Laru and A. Hajra, Org. Lett., 2019, 21, 5606.

11. NMR spectra [¹H, ¹³C{¹H}, ¹⁹F, and ³¹P] of synthesized products



S33



S34





S36





























































































-94.74















.

-94.96





.







-94.83





Solvent : CDCl₃















¹⁹F NMR : 376.5 MHz Solvent : CDCl₃






























































































Solvent : CDCl₃





